Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis

被引：3

作者：

Huang, Ye ^{[1
]}

Choo, Charlene ^{[2
]}

Hancock, Shelley ^{[3
]}

Ciulla, Thomas A. ^{[4
]}

Wykoff, Charles C. ^{[5
]}

Shantha, Jessica G. ^{[2
]}

Yeh, Steven ^{[1
]}

机构：

[1] Univ Nebraska, Stanley M Truhlsen Eye Inst, Dept Ophthalmol & Visual Sci, Med Ctr, Omaha, NE 68198 USA

[2] Univ Calif San Francisco, FI Proctor Fdn, 490 Illinois St, San Francisco, CA 94158 USA

[3] Clearside Biomed Inc, Alpharetta, GA USA

[4] Indiana Univ Sch Med, Indianapolis, IN USA

[5] Retina Consultants Texas, Houston, TX USA

来源：

JOURNAL OF VITREORETINAL DISEASES | 2024年 / 8卷 / 04期

基金：

美国国家卫生研究院;

关键词：

suprachoroidal delivery; triamcinolone acetonide; Xipere; macular edema; noninfectious uveitis; POSTERIOR; ACETONIDE; SPACE; INTERMEDIATE; IMPLANT;

D O I：

10.1177/24741264241246314

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. Methods: A synthesis of the literature was performed. Results: In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration. The drug-delivery system targets the suprachoroidal space using a microneedle-based device and has a favorable pharmacokinetic profile. Suprachoroidally administered investigational therapies have also been assessed in clinical trials for other posterior segment diseases, including diabetic ME, retinal vein occlusion, age-related macular degeneration, and choroidal melanoma. Conclusions: The safety and efficacy of suprachoroidal corticosteroid injections to treat uveitic ME have been shown in recent phase III clinical trials. Multiple programs are also investigating this modality of drug delivery for use in many other retinal and choroidal pathologies.

引用

页码：401 / 409

页数：9

共 46 条

[1]

[Anonymous], CLINICALTRIALSGOV

[2]

Aura Biosciences, 2022, A phase 1B/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety and efficacy of light-activated AU-011 for the treatment of subjects with small primary choroidal melanoma

[3]

Aura Biosciences, 2022, A Phase 2 Open-Label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) via Suprachoroidal Administration in Subjects with Primary Indeterminate Lesions and Small Choroidal Melanoma

[4]

Aura Biosciences, Aura Biosciences

[5] Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema A Randomized, Double-Masked, Parallel-Design, Controlled Study [J].

Barakat, Mark R. ;

Wykoff, Charles C. ;

Gonzalez, Victor ;

Hu, Allen ;

Marcus, Dennis ;

Zavaleta, Eric ;

Ciulla, Thomas A. .

OPHTHALMOLOGY RETINA, 2021, 5 (01) :60-70

[6] Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study [J].

Campochiaro, Peter A. ;

Wykoff, Charles C. ;

Brown, David M. ;

Boyer, David S. ;

Barakat, Mark ;

Taraborelli, Donna ;

Noronha, Glenn .

OPHTHALMOLOGY RETINA, 2018, 2 (04) :320-328

[7] Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes [J].

Chung, Sook Hyun ;

Mollhoff, Iris Natalie ;

Mishra, Alaknanda ;

Sin, Tzu-Ni ;

Ngo, Taylor ;

Ciulla, Thomas ;

Sieving, Paul ;

Thomasy, Sara M. ;

Yiu, Glenn .

HUMAN GENE THERAPY, 2021, 32 (13-14) :682-693

[8]

Ciulla T, 2022, AM J MANAG CARE, V28, pS243, DOI 10.37765/ajmc.2022.89270

[9] Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Future Directions [J].

Ciulla, Thomas ;

Yeh, Steven ;

Hariprasad, Seenu M. .

OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2022, 53 (07) :361-366

[10]

Clearside Biomedical Inc, 2021, clinicaltrials.gov

← 1 2 3 4 5 →